Aside from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and in good shape sufficient to tolerate FCR therapy, may still be great candidates for that latter, Along with the gain becoming that this remedy might be concluded in 6 months while ibrutinib should be taken indefinitely. This option can be specially important for non-compli